An imbalance both of immune signaling proteins and mediators of the itch response was found in the bloodstream of people with epidermolysis bullosa (EB) — for whom itch is a common and debilitating disease symptom — a study discovered. Given the findings, therapies targeting these proteins may be a…
Amryt Pharma has completed its rolling submission of an application to the U.S. Food and Drug Administration seeking the approval of Filsuvez (Oleogel-S10), a topical gel to heal skin wounds in people with junctional (JEB) and dystrophic epidermolysis bullosa (DEB). The new drug application (NDA) includes a request for priority review, which can…
This month’s Plunge for Elodie will be a virtual event for a first time, with participants worldwide encouraged to plunge into freezing waters at their respective locations to raise funds in support of new therapies for epidermolysis bullosa (EB). …
An analysis of the control group from the ESSENCE Phase 3 clinical trial, which tested the topical cream SD-101 in people with epidermolysis bullosa (EB), found overall improvements in wound closure and less pain over a three-month period. The unexpectedly high response rate…
Get regular updates to your inbox.